Anti-Cytochrome P450 1A2 [3B8C1]
Invented by Ayham Alnabulsi from Vertebrate Antibodies Limited
Invented at Vertebrate Antibodies Limited
- Datasheet
- References (2)
- Inventor Info
Info
Catalogue Number | 152163 |
Applications | IHC WB |
Antigen/Gene or Protein Targets | Cytochrome P450 1A2 (CYP1A2) |
Reactivity | Human |
Relevance | Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin. |
Host | Mouse |
Immunogen | Rat cytochrome P450 proteins |
Positive Control | IHC: formalin-fixed, paraffin-embedded normal liver sections; western blot: recombinant P450 |
Subclass | IgG1 kappa |
Myeloma Used | P3X63Ag8.653 |
Strain | Balb/c |
Research Area | Cancer, Cardiovascular, Cell Signaling & Signal Transduction, Metabolism |
References: 2 entries
Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162.
Profiling the expression of cytochrome P450 in breast cancer.
Europe PMC ID: 20716162
Add a reference
References: 2 entries
Murray et al. 2010. Histopathology. 57(2):202-11. PMID: 20716162.
Profiling the expression of cytochrome P450 in breast cancer.
Add a reference